Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $6.13.
Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Catalyst Pharma, and Exelixis. According to TipRanks, Catanzaro has an average return of 0.3% and a 35.32% success rate on recommended stocks.
Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.57.
See Insiders’ Hot Stocks on TipRanks >>
Based on Nurix Therapeutics’ latest earnings release for the quarter ending August 31, the company reported a quarterly revenue of $18.47 million and a GAAP net loss of $36.98 million. In comparison, last year the company earned a revenue of $10.79 million and had a GAAP net loss of $45.71 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nurix Therapeutics (NRIX) Company Description:
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company’s pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Read More on NRIX:
- Nurix Therapeutics price target lowered to $9 from $12 at Morgan Stanley
- Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
- FDA puts partial clinical hold on Nurix’s Phase 1 NX-2127-001 study
- Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
- Cathie Wood’s ARK Investment bought 140K shares of Nurix Therapeutics today
